Singapore: Medidata, global provider of cloud-based solutions for clinical research in life sciences, has expanded its partnership with Peking University Clinical Research Institute (PUCRI) for everaging the research institute's extensive clinical development network, expertise and resources.

Partnership will accelerate the adoption of the Medidata Clinical Cloud platform across China and, in doing so, optimize local drug development programs by bringing operational efficiencies and greater speed to clinical trials.

"We are delighted to strengthen our partnership with Medidata," Mr Weigang Fang, vice president, Peking University Health Science Center and director of PUCRI. "In China, paper-based clinical trials are still mainstream, especially at Chinese domestic companies. By working with Medidata, we look forward to further advancing clinical development in the country, serving as a bridge between globally-leading technology and innovative drug development."

Professor Yangfeng Wu, executive associate director, PUCRI, agreed, "The enhanced partnership between PUCRI and Medidata will provide better services and inject new vitality in drug development in China."

Combining cutting-edge, cloud-based solutions with deep expertise in clinical development, Medidata and PUCRI have collaborated for several years to introduce innovative technology into clinical research in China. Together, they are helping life sciences companies improve operational efficiencies and increase productivity across China's clinical research programs. In expanding their partnership, Medidata and PUCRI will provide life sciences companies in China with increased accessibility to industry-leading technology that streamlines clinical trials and, ultimately, helps to accelerate the delivery of novel therapies to patients.

Mr Takeru Yamamoto, managing director, Medidata-Asia Pacific region, said, "We are thrilled to be working more closely with PUCRI to bring our globally-recognized cloud-based technology to China. Leveraging PUCRI's clinical trial expertise will enable us to serve more life sciences organizations in China and to accelerate drug development, allowing patients to access new therapies faster, both from the local market and around the world."